Topical Tranexamic Acid in Complex Cardiac Surgery: Does it Reduce Transfusion Need?

Overview

Información sobre este estudio

The goal of ths study is to determine the effectiveness of adding topical tranexamic acid (TXA) to our standard practice of care for patients undergoing redo or complex cardiac procedures. The study will use a control group for comparision.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria: 

  • Patients undergoing complex cardiac surgery (redo operations, combined operations such as CABG + valve, multiple valve).
  • Male or female.
  • Patients > 18 years of age.

Exclusion Criteria:

  • Patients < 18 years of age.
  • Patients with allergy to TXA.
  • Patients with prior history of thrombosis.
  • Patients who cannot grant informed consent.
  • Patients with coagulopathic conditions such as factor deficiencies, factor inhibitors, heparin induced thrombocytopenia, or use of intravenous anticoagulants other than heparin at the time of cardiovascular surgery.
  • Patients who have received oral therapy with clopidogrel, prasugrel, rivaroxaban or dabigatran within the past 3 days.
  • Patients who are taking chronic warfarin therapy who have not discontinued treatment and demonstrated an INRgreater than 1.5 prior to surgery.
  • Patients who are undergoing emergency open heart-surgery.
  • Patients for whom procedures for which the cardiopulmonary bypass time is expected to be < 30 minutes.
  • Patients for whom procedures for which the cardiopulmonary bypass is excepted to not be normothermic (temperature ≥ 35 degrees C).
  • Patients who cannot receive heparin.
  • Pregnant patients.

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Hartzell Schaff, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20305347

Mayo Clinic Footer